InvestorsHub Logo
Followers 4
Posts 1510
Boards Moderated 0
Alias Born 08/23/2010

Re: None

Monday, 12/24/2018 11:52:37 PM

Monday, December 24, 2018 11:52:37 PM

Post# of 4899
I’m optimistic at the approach of SRCO to the CBD market.
- The applications of CBD are numerous. As one example Epidiolex (a purified form of CBD) is FDA approved for treatment of seizures associated with Dravets and Lennox-Gastault syndromes.
- Despite the promise of CBD, it is important to avoid some pitfalls, as illustrated by Charlottes Web, a CBD supplier with established market share receiving a warning letter from FDA for product claims: https://www.fda.gov/newsevents/publichealthfocus/ucm484109.htm
- SRCO appears to be approaching it’s CBD as an organically produced ‘pharmaceutical grade’ product which should realize the market potential by providing the concentration and other attributes that the CBD should have.
- With some of the other developments in the federal de facto legalization of hemp in the recently passed farm bill (see my previous post), it appears that SRCO is well positioned in a promising sector

Jacob J. Rosenblum on what every lawyer knows.

“If the facts are against you, hammer the law. If the law is against you, hammer the facts. If the fact and the law are against you, hammer opposing counsel."

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SRCO News